Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Average Recommendation of “Moderate Buy” from Brokerages

Lantheus Holdings, Inc. (NASDAQ:LNTH) has been assigned an average rating of “Moderate Buy” from the seven brokerages that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $104.71.

Several equities analysts have weighed in on the company. Truist Financial reissued a “buy” rating and set a $82.00 price objective (up from $80.00) on shares of Lantheus in a report on Monday, February 26th. JMP Securities reiterated a “market outperform” rating and set a $100.00 price target on shares of Lantheus in a research note on Friday, February 23rd. B. Riley boosted their price objective on Lantheus from $95.00 to $99.00 and gave the company a “buy” rating in a research note on Thursday. Finally, StockNews.com upgraded shares of Lantheus from a “hold” rating to a “buy” rating in a research report on Saturday, January 13th.

Lantheus Trading Up 1.4 %

NASDAQ:LNTH opened at $62.33 on Friday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 5.45 and a current ratio of 5.80. The firm has a market cap of $4.27 billion, a price-to-earnings ratio of 13.43 and a beta of 0.53. Lantheus has a 52 week low of $50.20 and a 52 week high of $100.85. The firm has a 50-day moving average price of $60.66 and a two-hundred day moving average price of $62.99.

Lantheus (NASDAQ:LNTH) last posted its quarterly earnings data on Thursday, February 22nd. The medical equipment provider reported $1.59 EPS for the quarter, beating the consensus estimate of $1.33 by $0.26. The firm had revenue of $354.00 million during the quarter, compared to analyst estimates of $350.44 million. Lantheus had a net margin of 25.20% and a return on equity of 63.16%. On average, equities analysts expect that Lantheus will post 5.72 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, major shareholder Lantheus Alpha Therapy, Llc purchased 60,431,039 shares of the firm’s stock in a transaction dated Wednesday, March 6th. The shares were purchased at an average cost of $0.95 per share, for a total transaction of $57,409,487.05. Following the completion of the transaction, the insider now directly owns 116,773,394 shares in the company, valued at approximately $110,934,724.30. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, Director Mary Anne Heino sold 93,863 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $65.31, for a total value of $6,130,192.53. Following the sale, the director now owns 251,643 shares in the company, valued at $16,434,804.33. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, major shareholder Lantheus Alpha Therapy, Llc acquired 60,431,039 shares of the company’s stock in a transaction that occurred on Wednesday, March 6th. The shares were acquired at an average cost of $0.95 per share, with a total value of $57,409,487.05. Following the purchase, the insider now directly owns 116,773,394 shares of the company’s stock, valued at approximately $110,934,724.30. The disclosure for this purchase can be found here. Insiders sold a total of 94,545 shares of company stock worth $6,169,936 in the last quarter. 1.50% of the stock is owned by company insiders.

Institutional Trading of Lantheus

Several institutional investors and hedge funds have recently modified their holdings of LNTH. Tucker Asset Management LLC raised its position in shares of Lantheus by 239.0% during the 3rd quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 282 shares in the last quarter. Principal Securities Inc. purchased a new stake in Lantheus during the fourth quarter valued at about $28,000. First Horizon Advisors Inc. lifted its stake in Lantheus by 97.0% during the third quarter. First Horizon Advisors Inc. now owns 457 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 225 shares during the last quarter. West Tower Group LLC boosted its holdings in shares of Lantheus by 534.1% in the 4th quarter. West Tower Group LLC now owns 520 shares of the medical equipment provider’s stock worth $32,000 after purchasing an additional 438 shares in the last quarter. Finally, Parkside Financial Bank & Trust increased its position in shares of Lantheus by 60.2% during the 2nd quarter. Parkside Financial Bank & Trust now owns 426 shares of the medical equipment provider’s stock valued at $36,000 after purchasing an additional 160 shares during the last quarter. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.